

Challenges Identified in FY13 and Roadmap to FY16

Terumo Corporation
President and Representative Director

Yutaro Shintaku


05.08.2014

FY13 Performance

- Achieved increase in sales and profit thanks to weaker yen
- Gap with the Mid-Term Plan (Profit in particular)


Sales

USD/EUR = 95/123, BJPY



*Operating Profit

USD/EUR = 95/123, BJPY



*Excl. amortization of goodwill and intangibles with related to the acquisition of CaridianBCT

Actions for Closing the Gap

- 1 Change Operations with “Company-led Management”**
- 2 Complete TCVS Quality System Improvement**
- 3 Reinforce Initiatives for Profitability Improvement**
- 4 Accelerate Shift to Higher-Margin Products**
- 5 Write off Assets of Certain Businesses**

1 Change Operations with “Company-led Management”

Company-led Management (As of April 1st 2014)

Shift from Matrix Management to Company-led Management in order to globally integrate and align businesses, functions and regions



Operation Changes



Business

- Redefine accountability for business performance
- Delegate authority to speed up decision-making

Corporate

- Implement corporate strategies
- Establish global management infrastructure

3-Company, 9-Division Structure



2 Complete TCVS Quality System Improvement

Towards Early Completion

- Requested corrections to operations and verification of the new system
- Already submitted a work plan to FDA
- Estimated additional cost of approximately ¥3.0 Billion for re-inspection in FY14

Other Manufacturing Facilities

- Passed FDA inspections without major issues in the past 3 years

3 Reinforce Initiatives for Profitability Improvement

Challenges

General Hospital

Must improve profitability with the core businesses

Cardiac & Vascular

Retain profitable growth

Blood Management

Slow down of blood transfusion market in developed countries

Corporate

Must enhance corporate functions and improve efficiency

Actions

- ✓ Established a team dedicated for profitability improvement
- ✓ Recover from margin related issues
- ✓ Set profitability target
- ✓ Improve margin by moving production abroad (mainly Vietnam)
- ✓ Expand presence in developing countries with higher-margin products
- ✓ Improve margin by enhancing production in Asia (India and Vietnam)
- ✓ Redefine roles of corporate functions
- ✓ Reform supply-chain management
- ✓ Established a team dedicated to lowering procurement cost

4 Accelerate Shift to Higher-Margin Products

General Hospital

- Focus on higher-margin products
- Revise regional strategy for basic commodities
- Grow portion of highly profitable DM and D&D

Cardiac & Vascular



- Coronary: expand presence with the new DES, Ultimaster
- Peripheral: develop full product lines and launch globally
- Neurovascular: continue to launch new non-coil products

Blood Management

- Focus on therapeutic apheresis, Spectra Optia
- Expand automated blood component processing system

Roadmap to FY16

- **Secure a foothold in FY13-14**
 - ✓ Write off Assets of Certain Businesses
- **Target OP20% by FY16**
- **Capital expenditure will peak out**
 - ✓ Balance investment and depreciation
- **Facilitate R&D for the next growth driver (ART Company)**
- **Continue to look out for M&A opportunities**



*Excl. amortization of goodwill and intangibles with related to the acquisition of CaridianBCT

IR Contact

Terumo Corporation

Corporate Communication (IR) Dept.

E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.